• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec11
Mesoblast Limited Announces Remestemcel-L Superiority Over Ruxolitinib in Treating SR-aGvHD
23:22
Nov5
Mesoblast's Chronic Lower Back Pain Phase III Study Data to be Discussed by FDA
00:02
Oct22
Mesoblast Limited Reports Ryoncil® Sales Growth and Plans for Key Trials
10:37
Oct8
Analyst McCarthy Gives Mesoblast Strong Buy Rating
16:21
Oct7
Shapiro Recommends Mesoblast Limited in Healthcare Sector
05:06
Oct6
Mesoblast Limited Reports 66% Growth in Ryoncil® Sales to $21.9 Million
23:26

Schedules & Filings

Schedules
Filings
Aug28
Earning Release(EST)

FY2025 Q4 Earning Release (USD) Revenue 7.021 M, Net Income -27.1 M, EPS -0.2128

Feb26
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 1.578 M, Net Income -23.97 M, EPS -0.21

Aug28
Earning Release(EST)

FY2024 Q4 Earning Release (USD) Revenue 1.257 M, Net Income -27.71 M, EPS -0.2523

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
ASPC
24.010
+78.91%
+10.590
PCLA
0.4050
+74.49%
+0.173
DTCK
0.3951
+66.08%
+0.157
SOPA
1.820
+58.26%
+0.670
ECDA
1.150
+46.50%
+0.365
GAUZ
1.470
+44.12%
+0.450
CELG.RT
0.0698
+39.60%
+0.020
ASPCR
0.2500
+38.89%
+0.070
PAVS
2.170
+37.34%
+0.590
CUE
0.3248
+34.77%
+0.084
View More